N.J. Jury Finds For Defendant Novartis In Zometa Jaw Injury Trial

N.J. Jury Finds For Defendant Novartis In Zometa Jaw Injury Trial

NEW BRUNSWICK, N.J. - (Mealey's) A New Jersey state court jury on May 15 returned a defense verdict for Novartis Pharmaceuticals Corp. in a Zometa jaw injury case, a source told Mealey Publications (Beverly Meng v. Novartis Pharmaceuticals Corp., No. MID-L-7670-07-MT, N.J. Super., Middlesex Co.).


In a 7-1 vote, the jury in the Middlesex County Superior Court found that Novartis did not fail to provide an adequate warning to plaintiff Beverly Meng's prescribing physician concerning the risk of osteonecrosis of the jaw (ONJ) from Zometa that the defendant knew or should have known, the source said. 

The jury did not have to answer any of the remaining five questions on the final verdict form. 

Meng was prescribed Zometa, an injectable bisphosphonate, to prevent bone damage after her *** cancer metastasized to her bones, the source said.  She alleges that the drug caused her to develop ONJ. 

The trial began April 22.  The jury began deliberating May 15 and returned its verdict in less than six hours, the source said. 

Meng is represented by Terrence Sweeney of the Law Offices of Terrence J. Sweeney in Quincy, Mass., John J. Beins of Beins, Goldberg & Hennessey in Chevy Chase, Md., and John J. Vecchione of Valad & Vecchione in Fairfax, Va.  Novartis is represented by Joe G. Hollingsworth, Katharine R. Latimer, Neil S. Bromberg and Jessica E. Kreig of Hollingsworth in Washington, D.C., and Beth Rose of Sills, Cummis & Gross of Newark, N.J. 

For all of your legal news needs, please visit www.lexisnexis.com/mealeys.

Lexis.com subscribers may search all Mealey Publications

Non-subscribers may search for Mealey Publications stories and documents at www.mealeysonline.com or visit www.Mealeys.com.

For more information about LexisNexis products and solutions, connect with us through our corporate site.